- Source type
- Government
- Access type
- Publisher
- Publisher
- Nature Medicine
- Added
- 2026-07-08
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
91
Government health research
- Publisher type
- Government research
- Bias profile
- Low
This source is strongest for safety and clinical outcomes and weaker for consumer context and regulatory status.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 66/100
- Context Source
- Clinical outcomes
- 90/100
- Primary Anchor
- Mechanism
- 90/100
- Primary Anchor
- Safety
- 92/100
- Primary Anchor
- Consumer context
- 88/100
- Strong Support
- Trial discovery
- 89/100
- Strong Support
Best used for
- Research synthesis
- Public-health context
- Safety resources
Weak for
- Primary endpoint extraction when a study is available
Used in Viral Vitalism
Aging Faster May Be Part of the Early-Onset Cancer Puzzle
Roles: Regulatory status
Related studies
No structured study record is currently attached to this source.
Related sources
ClinicalTrials.gov: ReMIND trial
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
CIRM: clinical and preclinical development awards
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 91
- Publisher
- CIRM
- Access
- Official
- Usage
- 1 connection
ClinicalTrials.gov: trial registry search for FourLight-3 context
Canonical source record for the republished rapid brief jamie-lynne-tarailo-breast-cancer-trial-close-to-home.
- Trust score
- 91
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 2 connections
FDA: approves sacituzumab govitecan-hziy for first-line TNBC indications
Canonical source record for the republished rapid brief fda-trodelvy-first-line-triple-negative-breast-cancer.
- Trust score
- 94
- Publisher
- FDA
- Access
- Official
- Usage
- 1 connection
FDA: bulk drug substances for compounding that may present significant safety risks
Canonical source record for the republished rapid brief fda-peptide-review-bpc-157-tb-500-mots-c-semax-epitalon.
- Trust score
- 94
- Publisher
- FDA
- Access
- Official
- Usage
- 1 connection
FDA: July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 94
- Publisher
- FDA
- Access
- Official
- Usage
- 2 connections